Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522626-12-00

Acronym

CFA-1048-2-25

Enrollment

Registered

2025-11-17

Start date

2025-12-18

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition.

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026